Hemalatha G. Rangarajan
A5062886533- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Prenatal Screening and Diagnostics
- Immune Cell Function and Interaction
- Renal Transplantation Outcomes and Treatments
- Neutropenia and Cancer Infections
- Blood groups and transfusion
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Mycobacterium research and diagnosis
- T-cell and B-cell Immunology
- Blood disorders and treatments
- Neurological Complications and Syndromes
- Platelet Disorders and Treatments
- Polyomavirus and related diseases
- Transplantation: Methods and Outcomes
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Autoimmune and Inflammatory Disorders Research
- Complement system in diseases
- Traumatic Brain Injury and Neurovascular Disturbances
Nationwide Children's Hospital
2016-2025
The Ohio State University
2016-2025
Indian Army
2011-2024
Creative Commons
2023
Army Hospital Research and Referral
2023
Hospital for Sick Children
2021
Penn State Milton S. Hershey Medical Center
2021
European Society for Blood and Marrow Transplantation
2021
Uppsala University
2021
Bexley Hall
2019
Abstract Mesenchymal stem/stromal cells (MSCs) are widely studied by both academia and industry for a broad array of clinical indications. The collective body data provides compelling evidence the safety MSC therapy. However, generally accepted proof therapeutic efficacy has not yet been reported. In an effort to generate more effective cell product, investigators focused on modifying processing protocols enhance intrinsic biologic activity. Here, we report Good Manufacturing...
Abstract There has been an increase in volume as well improvement overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center International Blood and Marrow Transplant Research of 79 904 autologous (auto) 65 662 allogeneic (allo) HCTs, we examined rates change autoHCT alloHCT over time trends OS 4 groups: non-Hispanic Whites (NHWs),...
Advances in allogeneic hematopoietic cell transplantation for sickle disease have improved outcomes, but there is limited analysis of healthcare utilization this setting. We hypothesized that, compared to late transplantation, early (at age
There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]-bone marrow [BM], or 7/8-peripheral [PB]) for hematopoietic cell transplantation (HCT) patients lacking HLA-matched related unrelated donor.
Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes patients with occurring after Haplo transplantation PTCy prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor conventional (MUD/conventional). We evaluated 2 cohorts: grade 4 acute (aGvHD) including 264 1163 recipients of MUD...
CARMIL2 deficiency is a rare combined immunodeficiency (CID) characterized by defective CD28-mediated T cell co-stimulation, altered cytoskeletal dynamics, and susceptibility to Epstein Barr Virus smooth muscle tumors (EBV-SMTs). Case reports associated with EBV-SMTs are limited. We describe herein novel homozygous variant (c.1364_1393del) in two Saudi Arabian male siblings born consanguineous parents who developed EBV-SMTs. protein expression was significantly reduced CD4+ cells CD8+ cells....
Patients with inherited CARMIL2 or CD28 deficiency have defective T cell signaling, but their immunological and clinical phenotypes remain largely unknown. We show that only one of three isoforms is produced functional across leukocyte subsets. Tested mutant alleles from 89 patients 52 families impair canonical NF-κB not AP-1 NFAT activation in cells stimulated via CD28. Like CD28-deficient patients, CARMIL2-deficient display recalcitrant warts low blood counts CD4+ CD8+ memory TREGs. Unlike...
To design and test a metric that reflects the overall quality safety performance of our blood marrow transplant program (BMT) use this to enhance care provided patients. The BMT index (BMTI) aggregates events missed opportunities for best practices into composite score clinical program, irrespective type or patient outcome. We selected 13 domains divided them based on time in continuum. journey has 3 general spheres: (1) pretransplant, (2) admission, (3) posttransplant follow-up long-term...
Socioeconomic status (SES) and race/ethnicity have been associated with the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HCT). Certain aspects graft-versus-host disease (GVHD) management, such as need for long-term care, prolonged immunosuppressive treatment, close follow-up complications, may exacerbate disparities. Adults (≥18 years) reported to Center International Blood Marrow Transplant Research who underwent a first allo-HCT acute leukemia, myelodysplastic...
To examine activity of ibrutinib in steroid-refractory chronic GVHD (SR-cGVHD) after FDA approval, we conducted a multicenter retrospective study. Data were standardly collected (N=270 from 19 centers). Involved organs included skin (75%), eye (61%), mouth (54%), joint/fascia (47%), GI (26%), lung (27%), liver (19%), genital (7%), other (4.4%). NIH severity was mild 5.7%, moderate 42%, severe 53%. 39% had overlap subtype. KPS ≥ 80% 72%. Median prednisone (mg/kg) 0.21 (0-2.27). Ibrutinib...
ABSTRACT Background In this study, we compared outcomes of intensified myeloablative conditioning regimens using large registry data from Japan (Japanese Society for Transplantation and Cellular Therapy) the United States (Center International Blood Marrow Transplant Research). Methods Adult patients who underwent their first allogeneic hematopoietic stem cell transplantation (HSCT) acute leukemia in remission between 2010 2018 cyclophosphamide plus total‐body irradiation (CY/TBI),...